Jian Xie - Fulgent Genetics COO President
| FLGT Stock | USD 17.02 0.61 3.46% |
President
Jian Xie is COO President of Fulgent Genetics
| Age | 59 |
| Address | 4399 Santa Anita Avenue, El Monte, CA, United States, 91731 |
| Phone | 626 350 0537 |
| Web | https://www.fulgentgenetics.com |
Jian Xie Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jian Xie against Fulgent Genetics stock is an integral part of due diligence when investing in Fulgent Genetics. Jian Xie insider activity provides valuable insight into whether Fulgent Genetics is net buyers or sellers over its current business cycle. Note, Fulgent Genetics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Fulgent Genetics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jian Xie over a month ago Acquisition by Jian Xie of 27 shares of Fulgent Genetics subject to Rule 16b-3 | ||
Jian Xie over a month ago Disposition of 689 shares by Jian Xie of Fulgent Genetics at 18.2593 subject to Rule 16b-3 | ||
Jian Xie over two months ago Disposition of 4345 shares by Jian Xie of Fulgent Genetics at 19.42 subject to Rule 16b-3 | ||
Jian Xie over six months ago Disposition of 6719 shares by Jian Xie of Fulgent Genetics at 24.65 subject to Rule 16b-3 |
Fulgent Genetics Management Efficiency
The company has return on total asset (ROA) of (0.0415) % which means that it has lost $0.0415 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1435) %, meaning that it created substantial loss on money invested by shareholders. Fulgent Genetics' management efficiency ratios could be used to measure how well Fulgent Genetics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.15 in 2025. Return On Capital Employed is likely to drop to -0.06 in 2025. At this time, Fulgent Genetics' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 35 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 49.4 M in 2025.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Jonah Kirkwood | Agilent Technologies | N/A | |
| Michael Boxer | Thermo Fisher Scientific | 58 | |
| Dominique Grau | Agilent Technologies | 66 | |
| Joseph LaPlume | Charles River Laboratories | 50 | |
| John Fesko | Natera Inc | 46 | |
| Jacob Thaysen | Agilent Technologies | 49 | |
| Michael Knell | Charles River Laboratories | 48 | |
| William Barbo | Charles River Laboratories | 64 | |
| William King | Danaher | 53 | |
| Robert Carson | Waters | 46 | |
| Elizabeth Rae | Waters | 60 | |
| Henrik AncherJensen | Agilent Technologies | 59 | |
| Robert Lutz | Danaher | 62 | |
| Solomon MBA | Natera Inc | 42 | |
| Brian Ellis | Danaher | 57 | |
| Matthew McGrew | Danaher | 53 | |
| Robert McMahon | Agilent Technologies | 55 | |
| Peter Hornstra | Thermo Fisher Scientific | 59 | |
| Samraat Raha | Agilent Technologies | 51 | |
| Charles Dadswell | Illumina | 65 | |
| Angela Lalor | Danaher | 59 | |
Management Performance
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0415 |
Fulgent Genetics Leadership Team
Elected by the shareholders, the Fulgent Genetics' board of directors comprises two types of representatives: Fulgent Genetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fulgent. The board's role is to monitor Fulgent Genetics' management team and ensure that shareholders' interests are well served. Fulgent Genetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fulgent Genetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Doreen Ng, VP Office | ||
| DABMG FACMG, Chief Director | ||
| Paul Kim, Chief Officer | ||
| Ming Hsieh, Chairman of the Board and Presidentident, CEO | ||
| Natalie Prescott, General Officer | ||
| Lawrence MD, Chief Officer | ||
| Ray Yin, President Pharma | ||
| Brandon Perthuis, Chief Officer | ||
| Jian Xie, COO President | ||
| Ellen Tsui, Vice Resources | ||
| Jakub Sram, Vice Sales | ||
| Paul CPA, Chief Officer |
Fulgent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fulgent Genetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.0415 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 335.22 M | ||||
| Shares Outstanding | 30.59 M | ||||
| Shares Owned By Insiders | 32.30 % | ||||
| Shares Owned By Institutions | 55.09 % | ||||
| Number Of Shares Shorted | 970.6 K | ||||
| Price To Earning | 3.95 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.